QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally?

• Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter.
• The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others.
• The company is targeting the commencement of clinical testing in the first half of 2026.  

Shares of Quoin Pharmaceuticals (QNRX) jumped as much as 39% on Tuesday after the company announced that the target loading concentrations for its two topical Rapamycin delivery technologies have been successfully achieved.

A Rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.

Path Forward

Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter. The company is targeting the commencement of clinical testing in the first half of 2026.  

The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others. Microcystic lymphatic malformations are benign vascular anomalies characterized by a collection of small, abnormal lymphatic vessels and cysts, often appearing as small, skin-colored to pinkish or even dark, blister-like vesicles on the skin.

Venous malformations, meanwhile, are present at birth, but not always visible, and are the most common type of vascular malformation. They are caused by veins that have not developed normally, resulting in tangled, enlarged vessels. Symptoms can include bluish or purplish spots, swelling, and pain.

Neither microcystic lymphatic malformations nor venous malformations have FDA-approved treatments.

Executive Take Away

According to Quoin CEO Michael Myers, initiating clinical development in microcystic lymphatic malformations and venous malformations will be complementary to the company’s pipeline.

The firm is now looking forward to the commencement of pivotal studies for QRX003 in Netherton Syndrome by the end of the year, with the help of the financing of up to $105.3 million closed in October. Quoin’s overall pipeline comprises four products in development for Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, and Scleroderma, among others.

“We believe that rapamycin loading concentrations of 4% and 5% in these proprietary delivery systems could potentially provide competitive advantages over other topical rapamycin formulations currently in development with similar drug loadings due to the ability of our technologies to optimize delivery of the drug at the target sites.”  
- Michael Myers, CEO, Quoin.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around QNRX stock jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.

QNRX stock is down by 59% this year. 

Also See: Chamath Palihapitiya Talks About US' Achilles Heel When It Comes To Rare Earths

For updates and corrections, email newsroom[at]stocktwits[dot]com

Share

·

Add us on